Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Transforming AI models into useful model organisms
These systems were not built to explain the brain. But treating them as model organisms that we can perturb and evolve will move us closer to that goal.
Transforming AI models into useful model organisms
These systems were not built to explain the brain. But treating them as model organisms that we can perturb and evolve will move us closer to that goal.
Cortical area remixes macaques’ knowledge blocks to solve new problems
When monkeys draw complex shapes, their neural activity reflects patterns of activation elicited by drawing simpler, component shapes.
Cortical area remixes macaques’ knowledge blocks to solve new problems
When monkeys draw complex shapes, their neural activity reflects patterns of activation elicited by drawing simpler, component shapes.
Getting grants feels good, but giving them is even better
As director of grants management at the Cure Alzheimer’s Fund, Kaela Singleton bets on bold science and shares in the joy of discovery.
Getting grants feels good, but giving them is even better
As director of grants management at the Cure Alzheimer’s Fund, Kaela Singleton bets on bold science and shares in the joy of discovery.